A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: A hoosier oncology group study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 2, 2005, Pages 169-172

  Ganjoo, Kristen N ^a,d   Robertson, Michael J ^a   Fisher, William ^b   Jung, Sin Ho ^c   McClean, John ^b   Huh, Sang Yoon ^b   Bufill, Jose ^b   Williams, Sheron ^b   Cripe, Larry D ^a  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b Hoosier Oncology Group   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

Gemcitabine; Low grade lymphoma; Non Hodgkin Lymphoma

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BLEOMYCIN; CISPLATIN; CLADRIBINE; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; PYRIMIDINE DERIVATIVE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEATH; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPHOCYTOMA; MALE; MONOTHERAPY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; RECURRENT DISEASE; RELAPSE; REMISSION; STATISTICAL ANALYSIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 17044378079     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000144812.74663.d0     Document Type: Article

References (24)

1. Armitage JO, Weisenburger DD. For the non-Hodgkin's Lymphoma Classification Project. new approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J Clin Oncol. 1998;16:2780-2795.
2. Nissen SI, Ersboll J, Hansen HS, et al. A randomised study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer. 1983;52:1-7.
3. Lawrence TS, Urba WJ, Steinberg SM, et al. Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute. J Radiat Oncol Biol Phys. 1988;14:417-424.
4. Mac Manus MP, Hoppe RT. Is Radiotherapy curative for stage I and II low-grade follicular lymphoma? Follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14:1282-1290.
5. Portlock CS. Management of the indolent non-Hodgkin's lymphoma. Semin Oncol. 1980;7:292-301.
6. Cheson BD. New prospects in the treatment of indolent lymphomas with purine analogues. Cancer J Sci Am. 1998;4:S27-36.
7. Kay AC, Saven A, Carrera CJ. 2-chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol. 1992;10:371-377.
8. Csoka K, Liliemark J, Larsson R, et al. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol. 1995;22(suppl 11):47-53.
9. Aleskog A, Larsson R, Hoglund M, et al. Evaluation of purine and pyrimidine analogues in human tumor cells from patients with low-grade lymphoproliferative disorders using the FMCA. Eur J Haematol. 1999;62:293-299.
10. Fossa A, Santoro A, Hiddemann W, et al. Gemcitabine as single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). J Clin Oncol. 1999;17:3786-3792.
11. Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol. 2001;113:185-187.
12. Zinzani PL, Magagnoli M, Bendandi M, et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol. 1998;9:1351-1353.
13. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000;18:2603-2606.
14. Sezer O, Eucker J, Jakob C, et al. Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine. Invest New Drugs. 2001;19:101-104.
15. Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol. 2000;18:2615-2619.
16. Savage DG, Rule SAJ, Tighe M, et al. Gemcitabine for relapsed or resistant lymphoma. Ann Oncol. 2000;11:595-597.
17. Dumontet C, Morschhauser F, Solal-Celigny P, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol. 2001;113:772-778.
18. Chau I, Harries M, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. Br J Haematol. 2003;120:970-977.
19. Gandhi V, Plunkett W, Du M, et al. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol. 2002;20:665-673.
20. Jung SH, Carey M, Kim KM. Graphical search for phase II clinical trials. Control Clin Trials. 2001;367-372.
21. Jennison C, Turnbull BW. Confidence intervals for a binomial parameter following a multistage test with application to MIL-STD 105D and medical trials. Technometrics. 1983;25:49-58.
22. Jung SH, Kim KM. On the estimation of the binomial probability in multistage clinical trials. Stat Med. 2003. In press.
23. Bass AJ, Gockerman JP, Hammett E, et al. Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. J Clin Oncol. 2002;20:2995-3000.
24. Rizzieri DA, Bass AJ, Rosner GL, et al. Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol. 2002;20:674-679.